In Phase A, participants will obtain distinctive doses and schedules of oral ABBV-744 tablet to discover safe dosing regimen. Added contributors will likely be enrolled for the identified monotherapy dosign regimen. In Segment B, individuals will get oral ruxolitinib and ABBV-744 will be offered as "incorporate-on" therapy. In Section C, https://abbv-744-and-other-brd4-i80235.thekatyblog.com/30942640/abbv-744-cancer-treatment-clinical-trials-an-overview